A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Phase of Trial: Phase I/II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Taladegib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2017 Planned End Date changed from 1 Nov 2022 to 1 Mar 2023.
- 07 Mar 2017 Planned primary completion date changed from 1 Apr 2023 to 1 Mar 2023.
- 07 Mar 2017 Status changed from not yet recruiting to recruiting.